IDXX Earnings Date: Nov 2, 2026 (Estimated) — IDEXX Laboratories, Inc.
NASDAQ · Healthcare · Diagnostics & Research
Updated
When is IDXX's next earnings date?
IDEXX Laboratories, Inc. (IDXX) is expected to report Q3 2026 earnings on Monday, November 2, 2026 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $3.72 on revenue of $1.19B.
How did IDXX do in its last earnings report?
In its most recent report on Aug 4, 2026 (Q2 2026), IDEXX Laboratories, Inc. posted EPS of $4.27 versus the $3.94 estimate, a beat of 8.4%. Revenue was $1.22B against a $1.20B estimate. The stock's 1-day post-earnings move was +3.6%.
How much does IDXX stock move after earnings?
IDXX beat EPS estimates in 8 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 10.1% (up or down) in the day after earnings.
About IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-04 | Q2 2026 | 3.94 | 4.27 | +8.38% | $1.22B | ✅ Beat | +3.57% | +4.92% | -3.99% |
| 2026-05-05 | Q1 2026 | 3.41 | 3.47 | +1.76% | $1.14B | ✅ Beat | -0.03% | -5.53% | -0.42% |
| 2026-02-02 | Q4 2025 | 2.93 | 3.08 | +5.12% | $1.09B | ✅ Beat | -4.60% | -3.86% | -5.21% |
| 2025-11-03 | Q3 2025 | 3.14 | 3.22 | +2.55% | $1.10B | ✅ Beat | +14.84% | +12.54% | +16.40% |
| 2025-08-04 | Q2 2025 | 3.30 | 3.50 | +6.06% | $1.11B | ✅ Beat | +27.49% | +22.88% | +19.40% |
| 2025-05-01 | Q1 2025 | 2.85 | 2.91 | +2.11% | $998.4M | ✅ Beat | +8.95% | +12.47% | +18.65% |
| 2025-02-03 | Q4 2024 | 2.40 | 2.53 | +5.42% | $954.3M | ✅ Beat | +11.13% | +8.94% | +4.63% |
| 2024-10-31 | Q3 2024 | 2.68 | 2.79 | — | $975.5M | ✅ Beat | -9.79% | -6.13% | -6.50% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $1.22B total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Product | 59.1% | $718.6M | +9.3% | $559.9M | $573.1M | $657.6M | $656.2M |
| Service | 40.9% | $498.0M | +10.2% | $394.4M | $425.4M | $451.9M | $449.1M |
By region
Q2 FY26 · $1.22B total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 63.5% | $773.0M | +7.7% | $604.0M | $654.9M | $717.9M | $705.0M |
| EMEA | 21.8% | $265.5M | +13.8% | $207.6M | $204.5M | $233.3M | $245.1M |
| Asia Pacific | 8.3% | $101.5M | +13.7% | $83.3M | $81.7M | $89.3M | $90.7M |
| CANADA | 4.2% | $50.8M | +8.8% | $38.3M | $37.3M | $46.7M | $41.4M |
| Latin America | 2.1% | $25.8M | +15.6% | $21.2M | — | $22.3M | $23.0M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.